A 24-Week Treatment of Pediatric Hemangioma with Oral Propranolol

Authors

  • Aziz Eghbali Department of Pediatrics, Arak University of Medical Sciences, Arak, Iran
  • Bahador Bagheri Department of Pharmacology, Semnan University of Medical Sciences, Semnan, Iran
  • Shabnam Hajiani Department of Pediatrics, Arak University of Medical Sciences, Arak, Iran
  • Vahid Mansouri Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:

Background: Hemangioma is a benign vascular tumor that shouldbe treated in problematic situations.Propranolol efficacy, target dose, range of age, duration of treatment and complications arenot conclusive for treatment of pediatric hemangioma. Our goal was to study efficacy and safety of propranolol for hemangiomatreating in children. Methods: A randomized, open label crossover trial with two twenty four-week treatment phases separated by a one-week washout period, was conducted in Amir-Kabir Hospital, Arak, Iran. Thirty two patients with age of 1 month to 15 years were randomized to receive either oral propranolol 2 mg/kg/day or receivedno treatment. The primary outcome measure was change in hemangioma size assessed at baseline, day 3, day 7 and every month. Results: At baseline, the mean surface area was 36.9±36.3 cm2. After 1 week of treatment, a decrease was seen in size of hemangiomas. After one month, a significant reduction was seen in size of lesionsin treatment group compared to observation group (30 cm2vs 16 cm2, p< 0.01). Significant reductions were present at other intervals (p

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Oral Propranolol: A Useful Treatment for Infantile Hemangioma

Background: Infantile haemangioma is the commonest childhood tumor. Several lines of treatment are available. Recent reports have focused on the value of propranolol in treating rapidly proliferating haemangioma. The aim of this study was to assess oral propranolol in treatment for facial haemangioma. Patients and Methods: Fifteen patients with rapidly proliferating infantile facial haemangioma...

full text

[Treatment of infantile hemangioma with propranolol].

Infantile hemangiomas are proliferative vascular disorders that occur in the pediatric airway, potentially causing airway narrowing and respiratory stress. It appears in 1 out 10 children, more frequently in girls. Hemangiomas are benign tumours that usually appear on the head or neck but may also occur in deep organs. Until recently, the most common medical therapy used was high-dose systemic ...

full text

oral propranolol for treatment of pediatric hemangioma (long-term follow-up)

purpose: to assess the effect and long-term results of oral propranolol in pediatric capillary hemangiomas. methods: four children aged 3 months to 5 years with periocular and orbital hemangioma of infancy (hoi) were treated with propranolol, 2 milligram per kilogram per day divided in 2 doses. propranolol was continued in all cases until the end of the first year of life and tapered over 2-3 w...

full text

Oral Propranolol for Circumscribed Choroidal Hemangioma

INTRODUCTION Several therapeutic approaches have been developed to treat choroidal hemangioma. However, all these therapies are associated with a potential risk of damaging the overlying retina. CASE REPORT We report a case of circumscribed choroidal hemangioma (CCH) in a 59-year-old man refractory to laser treatment. Visual acuity was 20/200 and a serous macular detachment was present. The C...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 16  issue 2

pages  808- 813

publication date 2017-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023